GBG Forschungs GmbH (German Breast Group)

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, et al. Journal article Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer (2016) Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, et al. Journal article Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients (2015) Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, et al. Journal article Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015) (2015) Untch M, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, et al. Journal article, Review article Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy (2015) Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner BM, Gerber B, et al. Journal article Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study (2015) Hein A, Lambrechts D, Von Minckwitz G, Haeberle L, Eidtmann H, Tesch H, Untch M, et al. Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (2014) Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Journal article Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial (2014) Mueller V, Gade S, Steinbach B, Loibl S, Von Minckwitz G, Untch M, Schwedler K, et al. Journal article Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, et al. Journal article